A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques
Cobb, R. R.; Nkolola, J.; Gilchuk, P.; Chandrashekar, A.; House, R. V.; Earnhart, C. G.; Dorsey, N. M.; Hopkins, S. A.; Snow, D. M.; Chen, R. E.; VanBlargan, L. A.; Hechenblaickner, M.; Hoppe, B.; Collins, L.; Tomic, M. T.; Nonet, G. H.; Hackett, K.; Slaughter, J. C.; Diamond, M. S.; Carnahan, R. H.; Barouch, D. H.; Crowe, J. E.
Show abstract
Human monoclonal antibody (mAb) treatments are promising for COVID-19 prevention, post-exposure prophylaxis, or therapy. However, the titer of neutralizing antibodies required for protection against SARS-CoV-2 infection remains poorly characterized. We previously described two potently neutralizing mAbs COV2-2130 and COV2-2381 targeting non-overlapping epitopes on the receptor-binding domain of SARS-CoV-2 spike protein. Here, we engineered the Fc-region of these mAbs with mutations to extend their persistence in humans and reduce interactions with Fc gamma receptors. Passive transfer of individual or combinations of the two antibodies (designated ADM03820) given prophylactically by intravenous or intramuscular route conferred virological protection in a non-human primate (NHP) model of SARS-CoV-2 infection, and ADM03820 potently neutralized SARS-CoV-2 variants of concern in vitro. We defined 6,000 as a protective serum neutralizing antibody titer in NHPs against infection for passively transferred human mAbs that acted by direct viral neutralization, which corresponded to a concentration of 20 g/mL of circulating mAb.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans 97%
- Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains 95%
- Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers 95%
Similar papers in this journal
- Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice 97%
- Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants 95%
- Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. 95%
Similar papers in this journal
- Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects Macaques from infection 95%
- A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques 94%
- The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice 94%
Similar papers in this journal
- Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses 94%
- Blockade of TGF-β signaling reactivates HIV-1/SIV reservoirs and immune responses in vivo 94%
- mRNA-1273 vaccination protects against SARS-CoV-2 elicited lung inflammation in non-human primates 93%
Similar papers in this journal
- Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms 96%
- SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern 94%
- Functional characterization and lineage analysis of broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.